These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6415747)

  • 1. Different behavioral mechanisms underlie tolerance to the anorectic effects of fenfluramine and quipazine.
    Rowland N; Carlton J
    Psychopharmacology (Berl); 1983; 81(2):155-7. PubMed ID: 6415747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anorexia and brain serotonin: development of tolerance to the effects of fenfluramine and quipazine in rats with serotonin-depleting lesions.
    Carlton J; Rowland N
    Pharmacol Biochem Behav; 1984 May; 20(5):739-45. PubMed ID: 6610879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for 5-HT2 receptor mediation in quipazine anorexia.
    Shukla R; MacKenzie-Taylor D; Rech RH
    Psychopharmacology (Berl); 1990; 100(1):115-8. PubMed ID: 2296618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences among 'serotonergic' anorectics in a cross-tolerance paradigm: do they all act on serotonin systems?
    Rowland N; Antelman SM; Kocan D
    Eur J Pharmacol; 1982 Jun; 81(1):57-66. PubMed ID: 7117371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chronic administration of fenfluramine and quipazine on body weight gain after ovariectomy and on brain serotonin receptor binding.
    Rowland N; Carlton J; Bartness T; Smith G
    Behav Neurosci; 1983 Jun; 97(3):502-5. PubMed ID: 6683563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of fenfluramine and other anorectic agents in different feeding and drinking paradigms in rats.
    Rowland NE; Antelman SM; Bartness TJ
    Life Sci; 1985 Jun; 36(24):2295-300. PubMed ID: 4010458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system.
    Garattini S; Mennini T; Bendotti C; Invernizzi R; Samanin R
    Appetite; 1986; 7 Suppl():15-38. PubMed ID: 2427023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.
    Quattrone A; Schettini G; di Renzo G; Tedeschi G; Preziosi P
    Brain Res; 1979 Sep; 174(1):71-9. PubMed ID: 487124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical and behavioral factors in the development of tolerance to anorectics.
    Streather A; Hinson RE
    Behav Neurosci; 1985 Oct; 99(5):842-52. PubMed ID: 3843304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that it is possible to cause anorexia by increasing release and/or directly stimulating postsynaptic serotonin receptors in the brain.
    Samanin R; Mennini T; Garattini S
    Prog Neuropsychopharmacol; 1980; 4(4-5):363-9. PubMed ID: 7220662
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of quipazine and D-fenfluramine, two serotonin-like drugs, on TSH secretion in basal and cold stimulated conditions in the rat.
    Di Renzo GF; Quattrone A; Schettini G; Preziosi P
    Life Sci; 1978 Jun; 22(21):1879-85. PubMed ID: 672433
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic anorexic and behavioural effects of the fenfluramine metabolite, norfenfluramine: an evaluation of its role in the actions of fenfluramine.
    Goudie AJ; Taylor M; Wheeler TJ
    Psychopharmacologia; 1974; 38(1):67-74. PubMed ID: 4851021
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparative anorexigenic activity and other pharmacological properties of quipazine and its N-acyl derivatives].
    Trubitsyna TK; Asnina VV; Mashkovskiĭ MD
    Farmakol Toksikol; 1986; 49(1):44-9. PubMed ID: 3948987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of initial body weight on anorexia and tolerance to fenfluramine in rats.
    Carlton J; Rowland N
    Pharmacol Biochem Behav; 1985 Oct; 23(4):551-4. PubMed ID: 4070331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of serotonin agonists on lordosis, myoclonus, and cytoplasmic progestin receptors in guinea pigs.
    O'Connor LH; Feder HH
    Horm Behav; 1983 Jun; 17(2):183-96. PubMed ID: 6885006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of a model for central serotonin receptor activation.
    Matthews WD; Smith CD
    Life Sci; 1980 Apr; 26(17):1397-403. PubMed ID: 6247593
    [No Abstract]   [Full Text] [Related]  

  • 17. Behavioral effects of quipazine in the cat.
    Trulson ME; Brandstetter JW; Crisp T; Jacobs BL
    Eur J Pharmacol; 1982 Mar; 78(3):295-305. PubMed ID: 6461558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quipazine-induced behavior in neonatal rat pups.
    Spear LP; Ristine LA
    Pharmacol Biochem Behav; 1981 Jun; 14(6):831-4. PubMed ID: 7255519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. d-Fenfluramine and salbutamol: two drugs causing anorexia through different neurochemical mechanisms.
    Garattini S; Samanin R
    Int J Obes; 1984; 8 Suppl 1():151-7. PubMed ID: 6534892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The time-structure of the anorectic effect of satietin.
    Sándor G; Knoll J
    Physiol Behav; 1985 May; 34(5):851-3. PubMed ID: 4034724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.